ArticleJCI insight2020
Dual-wavelength photo-killing of methicillin-resistant Staphylococcus aureus.
Article in JCI insight, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 32 citations in OpenAlex.
- The Use of Blue Light as an Antimicrobial Treatment Against Staphylococcus aureus: A Systematic Review.Lasers in surgery and medicine · 2026Pooled it
- Violet photobiomodulation: biological effects and health implications.Lasers in medical science · 2025Pooled it
- Smartphone-Guided Visible Light Modulation of RSNOs for Antimicrobial Activity via Controlled Nitric Oxide Release.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Dilating the aging clock with light.Innovation (Cambridge (Mass.)) · 2026Review
- Near-UVA Radiation at 405 nm: Germicidal Effect With and Without Sub-Lethal Conditions onPathogens (Basel, Switzerland) · 2026Article
- Enhancement and Limitations of Green-Spectrum Dual-Wavelength Irradiation in Porphyrin-Based Antimicrobial Strategies TargetingPharmaceutics · 2026Article
- Natural Biomolecules and Light: Antimicrobial Photodynamic Strategies in the Fight Against Antibiotic Resistance.International journal of molecular sciences · 2025Review
- Simultaneous Dual-Wavelength Laser Irradiation against Implant-Adherent Biofilms ofBioengineering (Basel, Switzerland) · 2024Article
- Blue Light Potentiates Antibiotics in Bacteria via Parallel Pathways of Hydroxyl Radical Production and Enhanced Antibiotic Uptake.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Antimicrobial Resistance: Is There a 'Light' at the End of the Tunnel?Antibiotics (Basel, Switzerland) · 2023Review
- An Approach to Improve Energy Efficiency during Antimicrobial Blue Light Inactivation: Application of Pulse-Width Modulation Dimming to Balance Irradiance and Irradiation Time.Antibiotics (Basel, Switzerland) · 2023Article
- Managing Corneal Infections: Out with the old, in with the new?Antibiotics (Basel, Switzerland) · 2023Review
- An antimicrobial blue light device to manage infection at the skin-implant interface of percutaneous osseointegrated implants.PloS one · 2023Article
- MRSA and Skin Infections in Psoriatic Patients: Therapeutic Options and New Perspectives.Antibiotics (Basel, Switzerland) · 2022Article
- How can biophotonics help dentistry to avoid or minimize cross infection by SARS-CoV-2?Photodiagnosis and photodynamic therapy · 2022Review
- Antimicrobial Blue Light for Prevention and Treatment of Highly InvasiveFrontiers in microbiology · 2022Article
- Antimicrobial blue light: A 'Magic Bullet' for the 21st century and beyond?Advanced drug delivery reviews · 2022Review
- Daily Administered Dual-Light Photodynamic Therapy Provides a Sustained Antibacterial Effect onAntibiotics (Basel, Switzerland) · 2021Article
- Genetic Factors Affect the Survival and Behaviors of Selected Bacteria during Antimicrobial Blue Light Treatment.International journal of molecular sciences · 2021Review
- Potentiated antimicrobial blue light killing of methicillin resistant Staphylococcus aureus by pyocyanin.Journal of photochemistry and photobiology. B, Biology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
With the effectiveness of antimicrobials declining as antimicrobial resistance continues to threaten public health, we must look to alternative strategies for the treatment of infections. In this study, we investigated an innovative, drug-free, dual-wavelength irradiation approach that combines 2 wavelengths of light, 460 nm and 405 nm, against methicillin-resistant Staphylococcus aureus (MRSA). MRSA was initially irradiated with 460-nm light (90-360 J/cm2) and subsequently irradiated with aliquots of 405-nm light (54-324 J/cm2). For in vivo studies, mouse skin was abraded and infected with approximately 107 CFUs of MRSA and incubated for 3 hours before irradiating with 460 nm (360 J/cm2) and 405 nm (342 J/cm2). Naive mouse skin was also irradiated to investigate apoptosis. We found that staphyloxanthin, the carotenoid pigment in MRSA cells, promoted resistance to the antimicrobial effects of 405-nm light. In addition, we found that the photolytic effect of 460-nm light on staphyloxanthin attenuated resistance of MRSA to 405-nm light killing. Irradiation of 460 nm alone did not elicit any antimicrobial effect on MRSA. In a proof-of-principle mouse skin abrasion infection model, we observed significant killing of MRSA using the dual-wavelength irradiation approach. However, when either wavelength of light was administered alone, no significant decrease in bacterial viability was observed. Moreover, exposure of the dual-wavelength irradiation to naive mouse skin did not result in any visible apoptosis. In conclusion, a dual-wavelength irradiation strategy may offer an innovative, effective, and safe approach for the treatment of skin infections caused by MRSA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.